Drugs / FMX-8
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02228655 | Oct 2014 → Apr 2015 | anemia due to chronic disorder | FerruMax Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT01873534 | Jun 2013 → Mar 2014 | anemia due to chronic disorder | FerruMax Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FMX-8 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02228655 ↗ |
| Modality | Protein / enzyme biologic | “FMX-8 is a fusion protein of the human hemojuvelin (HJV) protein.” NCT01873534 ↗ |
| Route | Intravenous | “FMX-8 will be administered as 30 min i.v. infusion.” NCT01873534 ↗ |